According to new scientific research, Raltegravir Is a Potent Inhibitor of XMRV and may prove useful in stopping XMRV replication. XMRV is the virus implicated in prostate cancer and Chronic Fatigue Syndrome.
Since the information broke that XMRV may be the missing link of information about what causes Chronic Fatigue Syndrome, the CFS world has been in an uproar. (Feel free to search more on this website for links to XMRV data.) Now a body of researchers have put their testing muscles to work studying this anti-retroviral compound called Raltegravir…
Forty-five compounds, including twenty-eight drugs approved for use in humans, were evaluated against XMRV replication in vitro. We found that the retroviral integrase inhibitor, raltegravir, was potent and selective against XMRV at submicromolar concentrations, in MCF-7 and LNCaP cells, a breast cancer and prostate cancer cell line, respectively. Another integrase inhibitor, L-000870812, and two nucleoside reverse transcriptase inhibitors, zidovudine (ZDV), and tenofovir disoproxil fumarate (TDF) also inhibited XMRV replication. When combined, these drugs displayed mostly synergistic effects against this virus, suggesting that combination therapy may delay or prevent the selection of resistant viruses.
Check out the link and feel free to add any additional details that you find out on this.
Thanks, Cinda Crawford
Your host
{ 1 trackback }
{ 1 comment… read it below or add one }
Cinda Crawford 04.02.10 at 4:06 pm
Thanks Alisyn for the RT on Twitter. I find that Twitter is a great mechanism to get the word out and I really appreciate you helping me with that. Many hugs, Cinda